Oncohematology

Oncological diseases are the second leading cause of death and hospitalization in Western countries. Although hematological tumors are not the most prevalent, research in this field has led to the development of molecular targets that have modified the treatment of other neoplasms.

In the CIMA Oncohematology Program, we have focused on the most prevalent diseases and those with the greatest social impact in this field such as leukemia, lymphoma and myeloma due to their prevalence in society as well as the experience of our researchers, who are world-renowned leaders in the field. The interaction between scientists and physicians at the Clínica Universidad de Navarra allows for the development of high-impact translational projects that may lead to personalized medicine initiatives.

Research in this program is centered on:
  • Understanding the mechanisms that lead to the development of hematological neoplasms and identifying possible targets that are therapeutically useful.

  • Developing blood biomarkers that help detect early premalignant stages and monitoring treatment response.

  • Identifying new therapeutic targets and designing new drugs for the most effective treatment of hematological tumors.

We are part of the ISCIII Thematic Network in Cancer Research and we participate in national and international projects. Our connections with the pharmaceutical industry contribute to the development of ongoing participation in clinical trials at the Clínica Universidad de Navarra.

 

News



"Interaction between scientists and doctors makes it possible to develop high-impact translational projects that can be personalized for leukemia, lymphoma and myeloma." , Dr. Felipe Prósper, Program Director.

Contact

Contact:
Marisol Ripa
Avda. Pío XII, 55
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 1010
msripa@unav.es